Literature DB >> 10507300

Canine X-linked severe combined immunodeficiency.

P J Felsburg1, B J Hartnett, P S Henthorn, P F Moore, S Krakowka, H D Ochs.   

Abstract

Canine X-linked severe combined immunodeficiency (XSCID) is due to mutations in the common gamma (gamma c) subunit of the IL-2, IL-4, IL-7, IL-9 and IL-15 receptors. The most striking clinical feature is a failure to thrive or 'stunted' growth. Recurrent or chronic infections begin at the time of decline of maternal antibody, usually between six and eight weeks of age. Affected dogs rarely survive past three to four months of age. The major pathologic feature of canine XSCID is a small, dysplastic thymus. Grossly identifiable lymph nodes, tonsils, and Peyer's patches are absent in XSCID dogs. During the neonatal period, XSCID dogs have few, if any, peripheral T cells and increased number of peripheral B cells. Some XSCID dogs do develop phenotypically mature, nonfunctional T cells with age, however, the absolute number of peripheral T cells remain significantly decreased compared to age-matched normal dogs. An interesting finding is that as soon as T cells begin to appear in XSCID dogs they rapidly switch from a CD45RA+ (naive) phenotype to a CD45RA- (activated or memory phenotype). One of the characteristic findings in XSCID dogs is an absent or markedly depressed blastogenic response of T cells in response to stimulation through the T cell receptor and when the necessary second messengers for cellular proliferation are directly provided that by-pass signals delivered through ligand-receptor interaction. The proliferative defect is due to the inability of T cells to express a functional IL-2 receptor. Canine XSCID B cells do not proliferate following stimulation with T cell-dependent B cell mitogens, however, they proliferate normally in response to T cell-independent B cell mitogens. Canine XSCID B cells are capable of producing IgM but are incapable of class-switching to IgG antibody production following immunization with the T cell-dependent neoantigen, bacteriophage phiX174. The number of thymocytes in the XSCID thymus is approximately 0.3% of the thymocytes present in the thymus of age-matched normal dogs. The proportion of CD4-CD8- thymocytes in XSCID dogs is increased 3.5-fold and the CD4+CD8+ population is decreased 2.3-fold. These findings demonstrate that (1) a functional gamma c is required for normal B and T cell function, (2) early T cell development is highly dependent upon a functional gamma c, and (3) B cell development can occur through a gamma c-independent pathway.

Entities:  

Mesh:

Year:  1999        PMID: 10507300     DOI: 10.1016/s0165-2427(99)00049-5

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  14 in total

1.  Severe papillomavirus infection progressing to metastatic squamous cell carcinoma in bone marrow-transplanted X-linked SCID dogs.

Authors:  Michael H Goldschmidt; Jeffrey S Kennedy; Douglas R Kennedy; Hang Yuan; David E Holt; Margret L Casal; Anne M Traas; Elizabeth A Mauldin; Peter F Moore; Paula S Henthorn; Brian J Hartnett; Kenneth I Weinberg; Richard Schlegel; Peter J Felsburg
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

2.  Ex vivo γ-retroviral gene therapy of dogs with X-linked severe combined immunodeficiency and the development of a thymic T cell lymphoma.

Authors:  Douglas R Kennedy; Brian J Hartnett; Jeffrey S Kennedy; William Vernau; Peter F Moore; Thomas O'Malley; Linda C Burkly; Paula S Henthorn; Peter J Felsburg
Journal:  Vet Immunol Immunopathol       Date:  2011-04-14       Impact factor: 2.046

3.  Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapy.

Authors:  Suk See Ting-De Ravin; Douglas R Kennedy; Nora Naumann; Jeffrey S Kennedy; Uimook Choi; Brian J Hartnett; Gilda F Linton; Narda L Whiting-Theobald; Peter F Moore; William Vernau; Harry L Malech; Peter J Felsburg
Journal:  Blood       Date:  2005-12-29       Impact factor: 22.113

Review 4.  Gene therapy studies in a canine model of X-linked severe combined immunodeficiency.

Authors:  Peter J Felsburg; Suk See De Ravin; Harry L Malech; Brian P Sorrentino; Christopher Burtner; Hans-Peter Kiem
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-24       Impact factor: 5.032

5.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

Review 6.  Thymopoiesis and T cell development in common gamma chain-deficient dogs.

Authors:  Peter J Felsburg; Brian J Hartnett; Terry A Gouthro; Paula S Henthorn
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

7.  T cell repertoire development in XSCID dogs following nonconditioned allogeneic bone marrow transplantation.

Authors:  William Vernau; Brian J Hartnett; Douglas R Kennedy; Peter F Moore; Paula S Henthorn; Kenneth I Weinberg; Peter J Felsburg
Journal:  Biol Blood Marrow Transplant       Date:  2007-08-02       Impact factor: 5.742

8.  Novel reporter systems for facile evaluation of I-SceI-mediated genome editing.

Authors:  Nina M Muñoz; Brian C Beard; Byoung Y Ryu; Ralf M Luche; Grant D Trobridge; David J Rawlings; Andrew M Scharenberg; Hans-Peter Kiem
Journal:  Nucleic Acids Res       Date:  2011-11-21       Impact factor: 16.971

9.  Keratinocyte antiviral response to Poly(dA:dT) stimulation and papillomavirus infection in a canine model of X-linked severe combined immunodeficiency.

Authors:  Jennifer A Luff; Hang Yuan; Douglas Kennedy; Richard Schlegel; Peter Felsburg; Peter F Moore
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

Review 10.  Partially corrected X-linked severe combined immunodeficiency: long-term problems and treatment options.

Authors:  Suk See De Ravin; Harry L Malech
Journal:  Immunol Res       Date:  2009       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.